Targeting APRIL in the Treatment of IgA Nephropathy
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
37801688
PubMed Central
PMC10937009
DOI
10.2215/cjn.0000000000000338
PII: 01277230-202403000-00021
Knihovny.cz E-zdroje
- MeSH
- IgA nefropatie * farmakoterapie MeSH
- imunoglobulin A MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- imunoglobulin A MeSH
Concord Repatriation General Hospital Concord Australia
Department of Cardiovascular Sciences University of Leicester Leicester United Kingdom
Department of Nephrology General University Hospital Charles University Prague Czech Republic
Department of Nephrology Juntendo University Faculty of Medicine Tokyo Japan
Division of Nephrology University of Alabama at Birmingham Birmingham Alabama
John Walls Renal Unit University Hospitals of Leicester NHS Trust Leicester United Kingdom
KJC Statistics Macclesfield United Kingdom
The Kidney and Transplant Practice Mount Elizabeth Novena Hospital Singapore
University of New South Wales Sydney New South Wales Australia
Zobrazit více v PubMed
Pitcher D Braddon F Hendry B, et al. . Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727–738. doi:10.2215/CJN.0000000000000135 PubMed DOI PMC
Selvaskandan H, Barratt J, Cheung CK. Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link. Int J Immunogenet. 2022;49(1):8–21. doi:10.1111/iji.12561 PubMed DOI
Lafayette RA Canetta PA Rovin BH, et al. . A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28(4):1306–1313. doi:10.1681/ASN.2016060640 PubMed DOI PMC
Han SS Yang SH Choi M, et al. . The role of TNF superfamily member 13 in the progression of IgA nephropathy. J Am Soc Nephrol. 2016;27(11):3430–3439. doi:10.1681/ASN.2015060677 PubMed DOI PMC
Kiryluk K Li Y Scolari F, et al. . Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187–1196. doi:10.1038/ng.3118 PubMed DOI PMC
Myette JR Kano T Suzuki H, et al. . A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 2019;96(1):104–116. doi:10.1016/j.kint.2019.01.031 PubMed DOI
Mathur M Barratt J Suzuki Y, et al. . Safety, tolerability, pharmacokinetics, and pharmacodynamics of VIS649 (sibeprenlimab), an APRIL-neutralizing IgG2 monoclonal antibody, in healthy volunteers. Kidney Int Rep. 2022;7(5):993–1003. doi:10.1016/j.ekir.2022.01.1073 PubMed DOI PMC
Kooienga L Suzuki Y Chacko B, et al. . Interim analysis (IA) of a global phase 2 randomized controlled trial of sibeprenlimab (VIS649), an APRIL-neutralizing monoclonal antibody, in IgA nephropathy. Abstract TH-PO991. 2022 American Society of Nephrology Kidney Week, Orlando, FL.
McCafferty K Follman K Pasetti M, et al. . Covid vaccine responses during Sibeprenlimab treatment of IgA nephropathy (IgAN): an interim analysis. Nephrol Dial Transplant. 2023;38(S1):gfad063a_3347. doi:10.1093/ndt/gfad063a_3347 DOI
Barratt J Hour B Kooienga L, et al. . POS-109 Interim results of Phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BION-1301 in patients with IgA nephropathy. Kidney Int Rep. 2022;7(2):S46. doi:10.1016/j.ekir.2022.01.121 DOI
Lafayette R Maes B Lin C, et al. . 36-Week efficacy & safety of atacicept 150 mg in the ORIGIN randomized, double-blind, placebo-controlled phase 2b study in IgAN and persistent proteinuria. ERA Congress. 2023. June 17, 2023.
